Br J Cancer

1. KANG MS, Katuwal NB, Ghosh M, Hong SD, et al
   JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.
   Br J Cancer. 2026;135:503-517.
   

   >> Share

   
   

   
   Clin Cancer Res

2. HARANO K, Nakao T, Nishio S, Katsuda T, et al
   Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study.
   Clin Cancer Res. 2026 Jul 30. doi: 10.1158/1078-0432.CCR-25-4887.
   

   >> Share

   
   

   
   J Natl Cancer Inst

3. BAHRAMI F, McLeod J, Pearce CL, Kushi LH, et al
   Effectiveness of opportunistic bilateral salpingectomy in preventing epithelial ovarian cancer: a population-based study.
   J Natl Cancer Inst. 2026 Jul 29:djag251. doi: 10.1093.
   

   >> Share

   
   

   
   PLoS One

4. 
   Editorial Note: NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin.
   PLoS One. 2026;21:e0354761.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share